Display options
Cite
Mazzanti A, Maragna R, Priori SG. Genetic causes of sudden cardiac death in the young. Curr Opin Cardiol. 2017;32(3):253-261doi: 10.1097/HCO.0000000000000391.
Mazzanti, A., Maragna, R., & Priori, S. G. (2017). Genetic causes of sudden cardiac death in the young. Current opinion in cardiology, 32(3), 253-261. https://doi.org/10.1097/HCO.0000000000000391
Mazzanti, Andrea, et al. "Genetic causes of sudden cardiac death in the young." Current opinion in cardiology vol. 32,3 (2017): 253-261. doi: https://doi.org/10.1097/HCO.0000000000000391
Mazzanti A, Maragna R, Priori SG. Genetic causes of sudden cardiac death in the young. Curr Opin Cardiol. 2017 May;32(3):253-261. doi: 10.1097/HCO.0000000000000391. PMID: 28266935.
Copy Download .nbib Format: NLM
Share it on

Curr Opin Cardiol. 2017 May;32(3):253-261. doi: 10.1097/HCO.0000000000000391.

Genetic causes of sudden cardiac death in the young.

Current opinion in cardiology

Andrea Mazzanti, Riccardo Maragna, Silvia G Priori

Affiliations

  1. aMolecular Cardiology Laboratories, IRCCS Maugeri Foundation bDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.

PMID: 28266935 DOI: 10.1097/HCO.0000000000000391

Abstract

PURPOSE OF REVIEW: In this article, we discuss the most recent and relevant studies published in the field of inherited arrhythmogenic disorders, focusing in particular on channelopathies (Long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia) and arrhythmogenic right ventricular cardiomyopathy (ARVC).

RECENT FINDINGS: We discuss the updated diagnostic criteria for channelopathies released by the European Society of Cardiology, the new results on the value of programmed electrical stimulation in patients with Brugada syndrome, and the recent evidences supporting a genotype-specific therapy for Long QT syndrome type 3. Moreover, we will present further insights into the clinical course and risk stratification of patients affected by ARVC, analyzing in particular the role of antiarrhythmic drugs for the prevention of life-threatening arrhythmias. Finally, we will explore the innovative therapeutic approaches that may be available in the future for patients with inherited arrhythmogenic disorders, such as the gene therapy.

SUMMARY: The review will aid physicians in their clinical work when managing patients with inherited arrhythmias and ARVC, providing the most recent information for diagnosis, risk stratification, and management.

Publication Types